川芎嗪注射液治疗急性ST段抬高型心肌梗死患者50例临床观察

发布时间：2018-05-17 21:17

本文选题：心肌梗死 + 川芎嗪注射液　；参考：《中医杂志》2016年21期

【摘要】：目的评价川芎嗪注射液后处理治疗急性ST段抬高型心肌梗死(STEMI)的有效性及安全性。方法将100例STEMI并接受经皮冠状动脉介入术的患者随机分为对照组和试验组各50例。对照组球囊扩张后予盐酸替罗非班氯化钠注射液10μg/kg冠状动脉内注射,术后连续0.2 mg/h静脉泵入48 h。试验组球囊扩张后给予盐酸替罗非班注射液10μg/kg冠状动脉内注射后,用川芎嗪注射液20 mg冠状动脉内注射,术后在对照组治疗基础上,加用盐酸川芎嗪注射液80 mg/d静脉滴注7天。比较两组治疗前后心电图ST段抬高幅度、肌酸激酶(CK)、肌酸激酶MB同工酶(CK-MB)、磷脂酶A2、冠脉校正TIMI帧数(CTFC)、左室射血分数(LV-EF)、血小板聚集功能测定(PAG%),并观察不良反应。结果试验组总有效率为93.6%,显著高于对照组83.3%(P=0.033)。治疗后两组CTFC、PAG%、ST段抬高幅度及CK、CK-MB、磷脂酶A2水平均明显下降,LV-EF水平显著上升(P0.01),且试验组CTFC、PAG%、ST段抬高幅度及CK-MB、磷脂酶A2水平均明显低于对照组(P0.05或P0.01)。两组患者均无明显不良反应。结论川芎嗪注射液后处理治疗STEMI疗效确切,可减少心肌损伤,安全性较好。
[Abstract]:Objective to evaluate the efficacy and safety of ligustrazine injection in the treatment of acute St segment elevation myocardial infarction. Methods 100 STEMI patients undergoing percutaneous coronary intervention were randomly divided into two groups: control group (n = 50) and trial group (n = 50). In the control group, 10 渭 g/kg tirofiban sodium chloride injection was injected into the coronary artery after balloon dilatation. After operation, 0.2 mg/h intravenous pump was injected into the control group for 48 h. In the experimental group, 10 渭 g/kg tirofiban hydrochloride was injected into the coronary artery after balloon dilatation, then 20 mg ligustrazine injection was injected into the coronary artery. On the basis of the treatment in the control group, the injection of ligustrazine hydrochloride for 80 mg/d was given intravenously for 7 days. The amplitude of St segment elevation, creatine kinase (CK), creatine kinase MB isoenzyme (CK-MBN), phospholipase A2 (phospholipase A2), coronary corrected TIMI frame count, left ventricular ejection fraction (LVEF) and platelet aggregation function were compared before and after treatment between the two groups. Results the total effective rate of the test group was 93.6, which was significantly higher than that of the control group (83.3%). After treatment, the levels of St segment elevation, CKCK-MBand phospholipase A _ 2 levels in both groups were significantly lower than those in the control group (P0.05 or P0.01), and the elevation amplitude of St segment, CK-MBand phospholipase A _ 2 levels in the trial group were significantly lower than those in the control group (P0.05 or P0.01). There were no significant adverse reactions in both groups. Conclusion after treatment of ligustrazine injection for STEMI is effective, can reduce myocardial injury and is safe.
【作者单位】：广州中医药大学第一临床医学院;广州中医药大学第一附属医院;

【相似文献】